Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Adierazpen geografikoek jatorrizko produktu baten izena eremu geografiko batetik babesten dute, eta adierazpen horri esker kalitate, ospe edo beste ezaugarri jakin batzuk ditu. Ezagutu zer diren, zein den erregistratzeko prozedura eta zer onura dituzten.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
79
resultados
Última actualización
13/01/2026 [06:57:00]
Resumen de: AU2024277588A1
Systems and methods for assessing risk for zoonotic disease, including salmonella, amongst an animal population at a production facility. A user can provide data in response to a plurality of data entry fields that can, at least partially, pertain to a procedure, operation, and/or equipment at the production facility. For each data entry field, the data provided by the user can be assigned a value. The value can correspond to predetermined value of a predetermined response that is identified as corresponding to the user inputted data. The assigned value can be adjusted by a weighted factor, which may correspond to a predicted impact the actions or information reflected by the user inputted data may have on the prevention of zoonotic disease. The assigned and/or adjusted values can be compiled to generate a risk assessment score, which can be used to determine a food safety index score and/or food safety plan.
Resumen de: CN120677168A
The present invention relates to a non-viable bacterial cell in which an immunogenic polypeptide fused to an autotransporter comprising a transmembrane linker and a transporter domain is displayed on the surface of the cell, as well as to formulations comprising such non-viable cells. The formulations are useful as oral vaccines.
Resumen de: CN121248735A
本发明属于生物技术领域，具体涉及一种具有增强TLR5配体活性的鞭毛蛋白突变体及其应用。选择鼠伤寒沙门氏菌鞭毛蛋白一个氨基酸突变位点，通过定点突变技术，利用大肠杆菌系统表达重组蛋白，经体外实验验证显示出良好的生物学活性，与野生型鞭毛蛋白突变体相比，能够更好的激活TLR5配体活性，为增强鞭毛蛋白佐剂和疫苗活性提供了良好的基础。
Resumen de: WO2026006835A1
Disclosed are engineered outer membrane proteins (OMPs) that comprise one or more extracellular loops from the Salmonella enterica serovar Typhimurium protein PagC or a functional portion thereof. Methods of expressing the engineered outer membrane proteins in a cell, such as a Gram-negative bacteria, to increase the production of outer membrane vesicles are also provided.
Resumen de: CN121248736A
本发明属于生物技术领域，具体涉及一种能够增强人源TLR5结合亲和力的鼠伤寒沙门菌鞭毛蛋白及其应用。本发明通过筛选并确定鞭毛蛋白的关键氨基酸突变位点，采用定点突变技术在大肠杆菌系统中实现重组表达。经体外实验验证，该衍生物能够显著激活TLR5配体功能。本发明解决了现有鞭毛蛋白在激活人源TLR5活性方面效果有限的问题，为鞭毛蛋白在疫苗、免疫治疗剂以及放射防护剂领域的应用提供了新的技术方案和理论基础。
Resumen de: CN121227763A
一种将猪霍乱沙门氏菌进行低内毒化改造的方法及其应用，它涉及疫苗领域，本发明通过基因工程技术对猪霍乱沙门氏菌弱毒株SC014的lipid A修饰，对猪霍乱沙门氏菌进行低内毒素化改造，成功构建了低内毒素的猪霍乱沙门氏菌突变体。改造后的猪霍乱沙门氏菌及其外膜囊泡在显著降低内毒素活性的同时，仍能有效激活免疫反应，实现了安全性与有效性的兼顾，为开发新型疫苗提供了新的思路和方法。
Resumen de: US2025387373A1
In one aspect, the disclosure relates to compositions and methods for dispersing exiting Salmonella biofilms and inhibiting formation of Salmonella biofilms. In various aspects, the disclosed compositions can be used in methods of treating a persistent Salmonella infection, including an asymptomatic infection. Such infections can colonize a variety of tissues, including the gall-bladder. Also disclosed are methods of treating typhoid fever. Also disclosed are methods for mitigating or preventing secondary outbreaks of typhoid fever by treating asymptomatic subjects who had been symptomatic for typhoid fever at a previous time. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.
Resumen de: CN120712079A
The present invention relates to the field of vaccine compositions. The invention more particularly relates to a prophylactic vaccine composition comprising killed intact bacteria intended for use in mammals and birds, said bacteria being wrapped with a cationic agent, in particular cationic nanoparticles.
Resumen de: WO2025255902A1
A primer and probe for detecting Salmonella pullorum, and a kit. The primer comprises SP-F and SP-R for detecting the target sequence of the Salmonella pullorum (SP) citE2 gene, and the probe is modified with a fluorescent reporter group and a fluorescent quenching group. By means of providing the primer pair of SP-F and SP-R, which pair specifically binds to the target sequence of the citE2 gene, and combining the primer pair with the probe, whic is used for specific recognition, the accurate and sensitive detection of Salmonella pullorum can be realized.
Resumen de: KR20250175381A
본 발명은 항암 물질인 아르기닌 디이미나아제 (arginine deiminase; ADI)를 발현하는 항종양 박테리아 균주 및 이의 용도에 관한 것으로, 본 발명에 따른 항암 물질 생산 시스템이 도입된 면역 활성능이 있는 살모넬라 균주는 우수한 면역 항암 효능을 나타내어, 기존 항암제와 함께 또는 독립적으로 암의 치료제로 사용될 수 있다.
Resumen de: MX2025009214A
The invention relates to protein bacteriocins (PBs) as therapeutic agents, and specifically to protein complexes comprising two or more PB molecules associated with a protein scaffold which comprises cognate immunity protein domains for the effector portions of the respective PBs. In particular, the invention provides an anti-bacterial protein complex comprising (a) a first PB molecule and a second PB molecule; and (b) an immunity protein scaffold comprising a first immunity protein domain and a second immunity protein domain; wherein the first and second immunity protein domains are non-covalently bound to the respective first and second PB molecules.
Resumen de: WO2024197078A2
Provided herein are compositions and methods for treating benign nervous system tumors, including schwannomas, using attenuated mutants of Salmonella typhimurium comprising a spiC deletion, and, optionally, one or more checkpoint inhibitors.
Resumen de: US2025375435A1
Disclosed herein are compositions and methods for treating a Salmonella infection. Disclosed herein are compositions and methods for inhibiting FraB in Salmonella. Disclosed herein are methods of increasing 6-phospho-fructose-aspartate within Salmonella bacteria.
Resumen de: US2025377362A1
The invention provides analytical methods for identifying and quantifying complex glycoconjugate compositions, in particular for the analysis of a glycoconjugate in a sample comprising at least 4 glycoconjugates.
Resumen de: WO2025246011A1
Provided are a method for enhancing the immunogenicity of a recombinant protein antigen and use thereof. The method comprises conjugating a polysaccharide with a recombinant protein antigen to form a nano-scale protein antigen. The polysaccharide is selected from sodium hyaluronate, chitosan, glucan, fucoidan, and sodium alginate. The recombinant protein antigen is a protein antigen derived from a bacterium. The bacterium belongs to the genus of Staphylococcus, Neisseria, Klebsiella, Escherichia, Clostridium, Salmonella, Shigella, Pseudomonas, Acinetobacter, Bordetella, Enterococcus, Haemophilus, Mycobacterium, or Streptococcus. The method not only improves the immunogenicity of the recombinant protein antigen, but also overcomes the defects of competitive immunoregulation and poor immune enhancement effects caused by bacterial capsular polysaccharide modification. The method also has the advantages of high clinical application value, simple starting material acquisition, low cost, good process stability, ease in scale expansion, high safety, and the like.
Resumen de: WO2024156739A1
The invention relates to a method for identifying a multi-parameter phenotype of microbiota. The method comprises (i) providing a sample comprising microbiota, (ii) labeling said microbiota with multiple labels, each of which binds a phenotypic parameter of said microbiota, (iii) detecting an intensity of the labelled phenotypic parameters of single cells of the microbiota by flow cytometry, and (iv) segmenting the single cells into bins based on the intensities of detected phenotypic parameters, wherein the distribution of single cells in bins represents a multi-parameter phenotype of said microbiota. The invention further relates to a system for identifying a multi-parameter phenotype of intestinal microbiota, a kit for identifying a multi-parameter phenotype of intestinal microbiota and methods for diagnosing a medical condition associated with microbiota, for example an inflammatory condition, such as an inflammatory bowel disease, in a subject.
Resumen de: WO2025245361A1
The present invention relates to antigen presentation to CD8+ T cells. Systems and methods are provided for efficient presentation of diverse peptide antigens and induction of stimulatory and regulatory CD8+ T cell responses.
Resumen de: US2025360189A1
An immunogenic gel compositions for oral administration and methods of immunizing an animal the methods including administering to the animal a therapeutically effective amount of an immunogenic gel composition comprising an antigen of an animal pathogen and a gel composition for oral administration.
Resumen de: WO2025238284A1
The present invention relates to a DNA construct that codes for a fusion protein comprising at least two enterohemorrhagic Escherichia coli antigens, for example, the antigens Int280, EspB, EspA, Stx2B, EspD, combinations or fragments thereof, vectors, fusion protein, immunisation methods and vaccines. The coded antigens can be fused Int280 and EspB of enterohemorrhagic Escherichia coli, forming a fusion protein with or without a connecting sequence between the two. The fused antigens can show the amino acid sequence SEQ ID No. 3 or SEQ ID No. 4 and are coded by the nucleotide sequence in SEQ ID No. 1 and SEQ ID No. 2. The construct can also comprise a signal sequence and a binding sequence for binding to the membrane of bacteria.
Resumen de: WO2025236040A1
Disclosed herein are solid lipid nanoparticles comprising a fatty acid esterified with polyethylene glycol. The polyethylene glycol is functionalised with an aptamer (i.e. targeting ligand). The nanoparticle may be loaded with an antibiotic or an antifungal, and a fluorescent compound. Also provided are their methods of preparation and their use in drug delivery and biosensing.
Resumen de: CN120202300A
The present invention relates to a DNA construct comprising: a gene encoding flagellin and a gene encoding an immunopotentiator (or adjuvant) protein. In order to achieve effective cancer treatment by selectively killing only cancer cells, the attenuated Salmonella strains of the present disclosure are designed to produce immunogenic substances in cancer tissue to induce a strong anti-cancer immune response to significantly inhibit tumor size in primary and metastatic cancers. Therefore, the strain can be advantageously used in a prophylactic or therapeutic composition for increasing survival rate.
Resumen de: MX2025009500A
The invention relates to the field of vaccine compositions. The invention more particularly relates to a prophylactic vaccine composition that is intended for mammals and birds and comprises a killed whole bacterium, said bacterium being covered with a cationic agent, in particular cationic nanoparticles.
Resumen de: CN117838855A
The invention relates to a synthetic adhesive for limiting passage through mucus. Synthetic adhesives for reducing the proportion of targets that can traverse mucus and/or free cleavage are disclosed, as well as methods of using these synthetic adhesives to reduce mucosal penetration and/or free cleavage of targets.
Resumen de: CN120418260A
The present disclosure generally relates to improved methods for preparing glycoconjugates. The method includes conjugating a saccharide to a carrier protein using an acetoxyborohydride-containing reducing mixture prepared in situ.
Nº publicación: US2025345369A1 13/11/2025
Solicitante:
ACTYM THERAPEUTICS INC [US]
Actym Therapeutics, Inc
Resumen de: US2025345369A1
Provided are delivery immunostimulatory bacteria that have enhanced colonization of tumors, the tumor microenvironment and/or tumor-resident immune cells, and enhanced anti-tumor activity. The immunostimulatory bacteria are modified by deletion of genes encoding the flagella, or by modification of the genes so that functional flagella are not produced, and/or are modified by deletion of pagP or modification of pagP to produce inactive PagP product. As a result, the immunostimulatory bacteria are flagellin and/or pagP−. The immunostimulatory bacteria optionally have additional genomic modifications so that the bacteria are adenosine or purine auxotrophs. The bacteria optionally are one or more of asd−, purI−, and msbB−. The immunostimulatory bacteria, such as Salmonella species, are modified to encode immunostimulatory proteins that confer anti-tumor activity in the tumor microenvironment, and/or are modified so that the bacteria preferentially infect immune cells in the tumor microenvironment, or tumor-resident immune cells, and/or are modified to induce less cell death in immune cells than in other cells. Also provided are methods of inhibiting the growth or reducing the volume of a solid tumor by administering the immunostimulatory bacteria.
BOPI
Sede Electrónica
